MARKET

DNTH

DNTH

Dianthus Therapeutics Inc
NASDAQ
19.04
-0.99
-4.94%
After Hours: 19.05 +0.01 +0.05% 18:12 07/15 EDT
OPEN
20.19
PREV CLOSE
20.03
HIGH
20.19
LOW
18.86
VOLUME
176.06K
TURNOVER
--
52 WEEK HIGH
32.27
52 WEEK LOW
13.37
MARKET CAP
612.33M
P/E (TTM)
-6.6173
1D
5D
1M
3M
1Y
5Y
1D
Evercore ISI Sticks to Their Buy Rating for Dianthus Therapeutics (DNTH)
TipRanks · 1d ago
Dianthus Therapeutics’ DNTH103: A Promising Complement Inhibitor with Upcoming Catalysts
TipRanks · 1d ago
Dianthus Therapeutics (DNTH) Gets a Buy from Stifel Nicolaus
TipRanks · 1d ago
Weekly Report: what happened at DNTH last week (0707-0711)?
Weekly Report · 1d ago
Weekly Report: what happened at DNTH last week (0630-0704)?
Weekly Report · 07/07 11:13
William Blair Sticks to Their Buy Rating for Dianthus Therapeutics (DNTH)
TipRanks · 07/05 17:45
Dianthus Therapeutics Initiated at Outperform by William Blair
Dow Jones · 07/02 19:11
BUZZ-U.S. STOCKS ON THE MOVE-Investar, Steel Dynamics, Axos Financial
Reuters · 07/02 18:00
More
About DNTH
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).

Webull offers Dianthus Therapeutics Inc stock information, including NASDAQ: DNTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DNTH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DNTH stock methods without spending real money on the virtual paper trading platform.